Business Wire

FDA Approves Baxter’s HYQVIA for Treatment of Adults with Primary Immunodeficiency

DEERFIELD, Ill. & SAN DIEGO--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the United States Food and Drug Administration ...
Business Wire

Baxter Presents Real-World Data at American Society of Health System Pharmacists Meeting Demonstrating Smart Infusion Pump Electronic Medical Record (EMR) Integration May ...

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced data in collaboration with The University of Texas ...
FierceBiotech

PRESS RELEASE: Baxter and Halozyme Announce Collaboration For Development Of Subcutaneous GAMMAGARD LIQUID

Development of New Route to Administer GAMMAGARD LIQUIDâ„¢ 10% Could Make Home Therapy More Accessible; Collaboration Valued at Up To $47 Million DEERFIELD, Ill. and SAN DIEGO, Calif., September 10, ...
GEN

Phase III Trial Shows Near Equivalence of Baxter’s Subcutaneous IG Therapy to IV Product

Results show patients require just 7% more HyQ than IV product to achieve the same systemic IG levels. Baxter reported positive interim data from a Phase III clinical trial with its subcutaneous ...
AOL

Baxter Receives Marketing Authorization for HyQvia in European Union

BRUSSELS--(BUSINESS WIRE)-- Baxter International Inc. (NYS: BAX) and Halozyme Therapeutics, Inc., (NAS: HALO) today announced that the European Commission has granted Baxter marketing authorization in ...